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S U M M A R Y
Objectives: Multidrug-resistant tuberculosis (MDR-TB) is a threat to tuberculosis (TB) control. To guide TB
control, it is essential to understand the extent to which and the circumstances in which MDR-TB will
replace drug-susceptible TB (DS-TB) as the dominant phenotype. The issue was examined by assessing
evidence from genomics, pharmacokinetics, and epidemiology studies. This evidence was then
synthesized into a mathematical model.
Methods: This model considers two TB strains, one with and one without an MDR phenotype. It was
considered that intrinsic transmissibility may be different between the two strains, as may the control
response including the detection, treatment failure, and default rates. The outcomes were explored in
terms of the incidence of MDR-TB and time until MDR-TB surpasses DS-TB as the dominant strain.
Results and conclusions: The ability of MDR-TB to dominate DS-TB was highly sensitive to the relative
transmissibility of the resistant strain; however, MDR-TB could dominate even when its transmissibility
was modestly reduced (to between 50% and 100% as transmissible as the DS-TB strain). This model
suggests that it may take decades or more for strain replacement to occur. It was also found that while the
ampliﬁcation of resistance is the early cause of MDR-TB, this will rapidly give way to person-to-person
transmission.
© 2017 The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
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Mycobacterium tuberculosis is now the most lethal infectious
pathogen. In 2014, it caused 9.6 million cases of tuberculosis (TB)
and killed 1.5 million people worldwide.1 An alarming proportion
of these cases can be attributed to drug-resistant strains of M.
tuberculosis, which present an ever-growing threat to global TB
control.
The serial introduction of single anti-mycobacterial agents in
the 1940s (streptomycin),2 1950s (isoniazid),3 and 1960s (rifampi-
cin)4 saw the emergence of drug-resistant isolates, particularly
when these agents were used alone or intermittently.5,6 Between
1970 and 1990, there were numerous outbreaks of drug-resistant
TB involving strains resistant to two or more drugs.7 This
phenomenon necessitated the use of multidrug combination
therapies, with strong health programmes  the directly observed
treatment short-course (DOTS) strategy. DOTS, as it was originally
implemented, focused on drug-susceptible (DS) TB. Its aim was to
increase successful treatment outcomes and reduce drug resis-
tance by ensuring all TB patients were treated with multiple agents
for at least 6 months.
Despite these measures, since 1985, the world has seen a
constant rise in the levels of multidrug-resistant (MDR) TB, deﬁned
as M. tuberculosis with in vitro resistance to at least isoniazid and
rifampicin, the two most potent ﬁrst-line anti-TB drugs. The most
recent report suggests that these isolates accounted for at least 480
000 incident cases and 210 000 deaths worldwide in 2014.1
Extensively drug-resistant (XDR) strains, which are MDR-TB strains
with additional resistance to ﬂuoroquinolones and a second-line
injectable agent (kanamycin, amikacin, or capreomycin), have now
been found in every region of the world.1
Initially, public health agencies looked at the soundness of the
DS-TB control programmes as a means to ﬁx the problem: “While it
is important, on a clinical basis and epidemiologically in some
contexts, to care optimally for patients with MDR-TB, it is more
important to address the cause of MDR-TB and to ﬁx the
programme generating MDR-TB”.8 However, a new paradigm
has gradually emerged in MDR-TB control, with greater acknowl-
edgement that MDR-TB must be addressed directly. This paper
examines why this shift in thinking is necessary to control MDR-TB,
as well as the consequences of neglecting to address the problem of
MDR-TB directly. Evidence from genomics, pharmacokinetics (PK),
and epidemiology was reviewed. Mathematical modelling was
then used to synthesize the evidence into scenarios in which MDR-
TB and DS-TB vie for dominance.
Genomics
In the last decades, major advances in molecular biology have
increased our knowledge of the mechanisms of resistance to the
main anti-TB drugs, with the identiﬁcation of speciﬁc gene
mutations that are associated with drug resistance.9 This has also
allowed the detailed mapping of M. tuberculosis transmission
pathways, which has indicated typical epidemic spread of drug-
resistant strains of M. tuberculosis in most settings where this has
been evaluated.10
Unlike other bacteria, in which acquired drug resistance is
generally mediated through horizontal transfer of mobile genetic
elements, M. tuberculosis acquires drug resistance through
spontaneous chromosomal mutation, typically resulting in a
ﬁtness cost seen as a reduced growth rate in vitro.11 However,
this ﬁtness cost varies depending on the speciﬁc drug resistance-
conferring mutations, and mutations associated with no ﬁtness
cost have also been described.12–14 Indeed, other processes, such as
compensatory evolution and genetic co-selection, complicate the
picture. As an example, the genetic background of each strain inwhich a speciﬁc resistance-conferring mutation occurs can
modulate the ﬁtness impact of this mutation, such interaction
between genes being called epistasis.12
Resistance to rifampicin is the most pressing concern in TB
management, because it necessitates very long, expensive and
relatively toxic drug schedules and leads to poorer outcomes. The
identiﬁcation of speciﬁc compensatory mutations among clinical
strains of M. tuberculosis has improved our understanding of drug
resistance and ﬁtness.15–17 Rifampicin resistance is nearly always
caused by one of several possible point mutations to the rpoB gene,
which encodes a small part of the b-subunit of RNA polymerase
close to the catalytic centre of the enzyme.9,18,19 The so-called
rifampicin resistance-determining region (RRDR) covers 81 base
pairs encoding amino acids 507–533 in the b-subunit. Compensa-
tory mutations that ameliorate the ﬁtness costs of the common
rifampicin-resistance mutation rpoB R529C have been described in
the rpoA,rpoB, and rpoC genes, coding for different subunits of RNA
polymerase (a, b- and b0 subunits, respectively). Some clinical
rifampicin-resistant M. tuberculosis isolates have mutations
outside the detection regions (leading to false-negative rpo-b
tests), while other isolates reveal no rpo-b mutation at all. Two
efﬂux pumps (Rv2936 and Rv0783) over-expressed in the resistant
isolates are postulated to cause the rifampicin resistance pheno-
type in these M. tuberculosis strains.20
Pharmacokinetic variability
Drug resistance in M. tuberculosis is now recognized to result
from complex drivers, rather than simply from weak programmes
and inadequate adherence to therapy. Recent evidence suggests
that the emergence of drug resistance can occur despite better
than 98% treatment completion.21 There is increasing evidence
that variability in PK proﬁles between individuals (i.e., inter-
individual variability) is a more likely cause of the emergence of
drug resistance than non-completion of treatment.22,23 Previous
studies have shown that the PK of ﬁrst-line anti-TB drugs including
isoniazid,24 pyrazinamide,25 rifampicin,26 and ethambutol27 ex-
hibit marked inter-individual variability. Such variability in PK
occurs as a result of demographic characteristics such as sex, age,
ethnicity, and body weight, comorbidities, drug interactions, and
genetic polymorphisms affecting drug absorption, metabolism,
and elimination. PK variability in turn may lead to inadequate drug
exposure at the site of infection, facilitating the emergence of drug
resistance.21,22 For example, Calver et al. found in their clinical
study that low drug exposure (as measured by area under the
concentration–time curve (AUC) and peak concentrations (Cmax))
was the main driver of drug resistance despite meticulous DOTS.21
Similarly, Srivastava et al. predicted that 1% of patients with perfect
adherence would develop MDR-TB due to suboptimal drug
exposure as a manifestation of PK variability alone.22
Epidemiology
MDR-TB has emerged independently in many parts of the globe,
with early discovery in South Africa and a rapid rise in Eastern
Europe with the collapse of Soviet public health systems.28 MDR-
TB is now found in most countries around the world and the
proportion of new TB cases showing multidrug resistance is
increasing. Currently, the highest absolute numbers of MDR-TB
cases occur in the most populous countries: India and China.1 In
contrast, the highest proportions of isolates showing drug
resistance are found in Eastern Europe, with 32% and 76% of
new and previously treated cases, respectively, found to be MDR-
TB in Belarus.29 However, the true global incidence of MDR-TB is
unknown, the proportion of new cases tested for drug susceptibil-
ity is only 12% globally,1 and MDR-TB is spreading in countries with
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MDR-TB may be as high as 1000 per 100 000 population in Daru,
Papua New Guinea.30
On the basis of early evidence of the variable and slow
emergence of multidrug resistance decades after the introduction
of therapy, many argued that MDR-TB would not replace DS-TB.31
However, epidemiology studies now provide evidence to the
contrary. For example, studies have shown that the transmission of
drug-resistant strains (i.e., primary resistance) rather than
ampliﬁcation from susceptible strains (acquisition of resistance-
conferring mutations, i.e., acquired resistance) is the dominant
source of MDR-TB.32 Children are an indicator of strains being
transmitted within communities; a recent study in China showed
that children presenting with their ﬁrst episode of TB frequently
had MDR M. tuberculosis.33
Drug-resistant M. tuberculosis strains have several survival
advantages owing to the way in which TB is managed globally.
Firstly, because only a fraction of new cases in the world are tested
for resistance,1 MDR-TB has the opportunity to spread in the
community before detection. Universal use of GeneXpert for new
cases is being advocated to improve the detection of resistant cases
and hence inhibit their spread. Additionally in many countries
MDR-TB treatment has a large backlog of patients, delaying speciﬁc
therapy.34 Finally after treatment has begun, the treatment
regimen is toxic, slower to reduce the bacterial burden,35 and
less successful, leading to treatment failures and withdrawals,
giving further opportunity for MDR-TB to spread.36 For this reason,
it is possible to speculate (and this will be shown with
mathematical modelling) that all else being equal, MDR-TB is
likely to take over from DS-TB.
It is now possible to estimate the likely contribution of the
various pathways to MDR-TB, i.e. (1) primary transmission of MDR-
TB resulting in new or retreatment cases, or (2) the development of
drug resistance in patients infected with DS-TB following
inadequate drug exposure. Global MDR-TB rates and available
modelling data suggest that the primary transmission of MDR-TB
strains from person to person has become more frequent than
acquisition following treatment.32
If MDR-TB were not transmissible, its emergence would pose at
worst a small increased cost for health systems. MDR-TB
transmissibility, the relative likelihood of person-to-personFigure 1. Diagram illustrating several mechanisms for a greater proportion of multidrug
cases (left), highlighting that resistance ampliﬁcation through treatment non-completion
(1) lower rates of treatment success for appropriately treated MDR-TB patients by compa
will be MDR-TB (brown pathway); (2) lower rates of testing for drug resistance at ﬁrst pre
as such until re-presentation (orange pathway); and (3) a lower denominator, due to htransmission, is an important determinant of whether it will
come to dominate over DS-TB. The early hypothesis that resistance
is always associated with a loss of bacterial ﬁtness, and hence leads
to lower case fatality rates and decreased transmission of such
strains, has been disproved.6 Indeed, some isolates of MDR M.
tuberculosis appear to have no reduction in ﬁtness.
Observations and simple calculations show that most MDR-TB
is transmitted rather than mutated from pre-existing DS strains.
Figure 1 gives a simpliﬁed summary of the sources of MDR-TB
found in new and pre-treated cases. Much is often made of the high
ratio of MDR-TB isolates in retreated cases (global estimate >20%)
compared with new cases (global estimate 3.3%) of TB.1 However
the ratio does not necessarily indicate high rates of ampliﬁcation,
as illustrated in Figure 1.
These arguments combined provide a framework to consider
MDR-TB as an infection that can arise whenever ﬁrst-line agents
are used against DS-TB. Although the ampliﬁcation of resistance is
made worse by poor programmes, even well-functioning pro-
grammes should expect some MDR-TB as a result of natural
variability in population PK. Once MDR-TB has emerged, its
potential to displace DS-TB as the dominant phenotype depends on
features other than those that drive the original ampliﬁcation.
These may depend on the transmission rates in the community and
the detection and cure rates of the TB programme. The following
section uses mathematical models to explore these ideas and elicit
the key drivers of MDR-TB dominance.
Modelling drivers of MDR-TB burden
Despite the evidence presented above, there remains consider-
able debate as to the key drivers of the emerging drug-resistant TB
epidemic. Mathematical modelling can illuminate this discussion
by simulating the transmission dynamics in high-risk communi-
ties and identifying the primary factors that most strongly
contribute to the incidence and prevalence of drug-resistant
strains. In this section, the conditions under which one would
expect MDR-TB to become dominant and the time taken to
transition to the dominant type are examined.
For this purpose, the two-strain TB transmission model intro-
duced by Trauer et al. was used.37 The two-strain model allows for a
modiﬁed transmissibility, and detection rate, of the MDR-TB strain-resistant tuberculosis (MDR-TB) in retreatment cases (right) by comparison to new
 is not the only cause of the discrepancy (red pathway). Other explanations include:
rison to drug-susceptible tuberculosis (DS-TB), such that more retreatment episodes
sentation, such that many patients with transmitted MDR-TB will not be recognized
igh treatment success rates at the ﬁrst treatment episode.
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Additionally, the model allows for different treatment failure rates
according to the resistance proﬁle. A diagram of the model, along
with the ordinary differential equations and all parameter values
used, is provided in the Appendix.
Baseline parameters for the model were chosen to simulate
high prevalence conditions, in which TB is always endemic
regardless of the values of the modiﬁable parameters. In doing
this it was aimed to capture transmission dynamics seen in global
hotspots;37 however, the model was not speciﬁcally calibrated to a
particular country. Hence the aim was to make general qualitative
and semi-quantitative conclusions about model outcomes, rather
than speciﬁc quantitative predictions.
An ampliﬁcation pathway is included in the model structure,
representing acquired resistance, so that as long as DS-TB exists
and is treated, it will continue to supply MDR-TB patients. The
resultant equilibrium scenarios are one of two possibilities: either
both DS-TB and MDR-TB remain in circulation (this represents DS
being the dominant driver of TB transmission), or MDR-TB
outcompetes DS-TB, driving the latter to extinction.
The results, displayed in Figure 2, show the incidence of MDR-
TB and time to replacement of DS-TB with MDR-TB as a function of
the relative transmissibility and relative detection rate of MDR-TB
compared with DS-TB (time of replacement is deﬁned as the point
at which the incidence of MDR-TB exceeds the incidence of DS-TB).
Predictably, the higher the transmissibility of the isolate (moving
along the x-axis from zero to twice as ﬁt as DS-TB), the higher the
incidence of MDR-TB at equilibrium and the faster its progress to
replace DS-TB strains as the dominant strain population. In this
model, the MDR-TB burden depends more sensitively on the
relative strain transmissibility than it does on the relative
detection rate. Figure 2 indicates a clear delineation, such that if
the relative transmissibility of MDR-TB is more than approximately
80% of DS-TB, MDR-TB always comes to dominate, regardless of the
relative detection rate. Conversely, if the relative transmissibility of
MDR-TB is less than approximately 50%, DS-TB remains dominant
regardless of the relative detection rate.
The relative detection rate does inﬂuence the incidence and
dominance of MDR-TB in the interval in which MDR-TB transmits
50% to 80% asefﬁcientlyasDS-TB.A detection rate of MDR-TBequal to
that of DS-TB (as may be expected when GeneXpert is the ﬁrst-lineFigure 2. Left Equilibrium multidrug-resistant tuberculosis (MDR-TB) incidence as a fun
taken for MDR-TB incidence to overtake drug-susceptible tuberculosis (DS-TB) incidence
The simulations were terminated at 1000 years; hence the dark blue colour representsdiagnostic), would lead to very low levels of MDR-TB, whereas no
MDR-TB detection would lead to high incidence levels (Figure 2).
The equilibrium MDR-TB incidence and replacement time,
respectively, as functions of the unsuccessful live outcome rate
(i.e., default or failure) and the relative detection rates are shown in
Figure 3. In these graphs the impact of changes in transmissibility
(relative transmissibility is set at a ﬁxed value of 70%) is not
considered. The upper left-hand corner of each panel in Figure 3–
corresponding to the best case control scenario  ﬁnds DS-TB
dominates; however, as we move towards the lower right-hand
corner, MDR-TB begins to dominate. Surprisingly, in this case, the
MDR-TB burden is more sensitive to the relative detection rate than
it is to the treatment outcome. However, as the relative detection
rate increases, the treatment outcome becomes more important.
This calculation was repeated for a relative transmission ﬁtness of
100% and it was found that MDR-TB dominates under all
conditions, except zero treatment.
Laboratory ﬁndings suggest that compensatory mutations
occur in some isolates of MDR M. tuberculosis that potentially
allow the growth and transmissibility ﬁtness cost to be minimized
or completely overcome.38 Furthermore, modelling suggests that
strain replacement can occur even if the basic reproduction
number of the MDR-TB strain is less than that of the DS strain; that
is, even when there is a ﬁtness cost to drug resistance.37 Therefore,
the growing risk of the MDR-TB epidemic cannot be dismissed by
assuming that the relative ﬁtness of the mutant strains is
diminished, which in itself may not be a valid assumption.
The shortest time period for MDR-TB to overcome the less
resistant co-circulating strain is of the order of decades. Given this,
it would be possible to mistake the slow emergence of the resistant
strain for an absence of signiﬁcant burden at equilibrium. This may
help to explain the historical assumption that MDR-TB was a
temporary phenomenon resulting directly from non-completion of
therapy in individual patients, rather than a persistent challenge to
global control. Moreover, as the replacement time is of the order of
centuries under most proposed conditions (Figures 2 and 3), this
could also explain the observation that some countries have very
low rates of MDR-TB while others have extremely high rates, at
50 years following introduction of the antibiotics.
In Figure 4, the model output of the proportion of MDR-TB that
arises through transmission from person to person as a fraction ofction of relative transmissibility and relative treatment detection rate. Right: Time
, as a function of the relative transmissibility and relative treatment detection rate.
 no replacement of DS-TB with MDR-TB.
Figure 3. Left: Incidence of multidrug-resistant tuberculosis (MDR-TB) as a function of proportion default/failure rate as a fraction of all cases of active TB treated (x-axis) and
relative detection rate of MDR-TB compared to drug-susceptible tuberculosis (DS-TB) (y-axis). Right: Time to replacement of DS-TB with MDR-TB as a function of the same
variables. Replacement time is shown on a logarithmic scale. The simulations were terminated at 1000 years; hence the dark blue colour represents no replacement of DS-TB
with MDR-TB.
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MDR-TB arises through ampliﬁcation, as would be expected, given
that starting conditions are that there is no MDR-TB. After 10 years,
the proportion of MDR-TB is nearing its equilibrium state and
depends on the relative transmissibility of the MDR-TB.
In this model, the ampliﬁcation of MDR-TB from DS-TB serves as a
trigger, bringing MDR into existence, while ﬁtness cost and the
favourable conditions for replacement inadvertently brought about
by control programmes determine whether MDR will dominate.
Factors that drive MDR-TB replacement include low levels of
detection of MDR compared with DS-TB and higher default/failure
rates of MDR-TB than DS-TB. However, relative detection rates are
much more inﬂuential than relative default/failure rates.
Earlier models, such as those of Dye and Espinal, had a similar
structure but did not explore as broad a parameter space.39 In fact,
they did not allow that MDR-TB may be harder to detect than DS-Figure 4. Ratio of multidrug-resistant (MDR) cases of tuberculosis (TB) that are
transmitted versus acquired as a function of time (x-axis) and relative transmission
(Rel. Trans.).TB, or be more likely to fail therapy, effectively exploring only the
top left corner of the heat maps in Figures 2 and 3. As can be seen,
this is not a very interesting part of the parameter space and one in
which the MDR-TB transmission environment is unfavourable.
Further modelling work deﬁning the conditions under which
strain replacement may occur will be very useful in determining
the risk of additional or accumulated resistance, for example the
emergence of XDR-TB and resistance to newer agents such as
bedaquiline and delamanid.
Conclusions
Modelling demonstrates that TB with a resistant phenotype
may thrive even in the presence of some transmissibility ﬁtness
cost  a concerning possibility that needs to be appreciated by
public health policymakers. Current surveillance and reporting
systems are inadequate to estimate the extent of MDR-TB,40 and
the reporting requirements tend to obscure the magnitude of
primary transmission of drug-resistant TB,41 which is a critical
methodological ﬂaw that needs to be addressed urgently. Without
a renewed focus on the prevention, early diagnosis, and effective
treatment of MDR-TB cases, we are likely to witness MDR-TB
epidemic replacement in the coming decades, which could derail
progress towards global TB control and ultimate elimination.
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Appendix A.
Figure A1.
Model used for the modelling section of this paper; derived
from Trauer et al.37
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Figure A1. Model structure: red compartments with m subscripts = population
infected with multidrug-resistant tuberculosis (MDR-TB); thick blue arrow =
infection with drug-susceptible TB (DS-TB) in fully susceptible persons (l); thin
blue arrows = infection with DS-TB in partially immune persons (ld); thick red
arrow = infection with MDR-TB in fully susceptible persons (lm); thin red
arrow = infection with MDR-TB in partially immune persons (ldm). Susceptible
compartments (S) are divided into fully susceptible (subscript A) and partially
immune (subscript B), while latent compartments (L) are divided into early
(subscript A) and late (subscript B) latency.
Table A1
Parameter values and their deﬁnitions.
Parameter Meaning Value
Fixed disease parameters
e Early progression 0.072
k Transition to late latency 0.9
n Reactivation 0.004
g Spontaneous recovery 0.33
mi TB-speciﬁc death rate 0.15
mt Treated TB-speciﬁc death
rate
0.5 mi
h Ampliﬁcation 0.035
o Treatment modiﬁcation of
infectiousness
0.21
x Partial immunity 0.49
f Drug-susceptible
treatment rate
2
fm MDR-TB treatment rate 0.5
Fixed epidemiological parameters
p Birth rate Varied to population-
wide death rate
m TB-free mortality 0.016
r Infectious proportion 0.35
Modiﬁable parameters (baseline values)
i BCG vaccination rate 0.65
d Detection rate 0.72
dm MDR-TB detection rate 0
v Default rate 0.25
b Effective contact rate 38a
bm MDR-TB effective contact
rate
0.7b
Parameters modiﬁed
for Figure 2
Range
dm MDR-TB detection rate 0  d (i.e. 0  0.72)
bm MDR-TB effective contact
rate
0  2b (i.e. 0  76)
Parameters modiﬁed
for Figure 3
Range
dm MDR-TB detection rate 0  d (i.e. 0  0.72)
v Default rate 0  f (i.e. 0  0.5)
Parameters modiﬁed
for Figure 4
Range
bm MDR-TB effective contact
rate
0  b (i.e. 0  38)
TB, tuberculosis; MDR, multidrug-resistant; BCG, bacille Calmette–Guérin.
a Iteratively adjusted to match an incidence rate of 400 to 450 per 100 000 per
year.
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dSA
dt
¼ 1  ið ÞpN  l þ lm þ mð ÞSA
dSB
dt
¼ ipN þ ’T þ ’mTm  ld þ ldm þ mð ÞSB
dLA
dt
¼ lSA þ ld SB þ LB þ LBmð Þ  e þ k þ mð ÞLA
dLAm
dt
¼ lmSA þ ldmðSB þ LB þ LBmÞ  e þ k þ mð ÞLAm
dLB
dt
¼ kLA þ gI  ld þ ldm þ n þ mð ÞLB
dLBm
dt
¼ kLAm þ gIm  ld þ ldm þ n þ mð ÞLBm
dI
dt
¼ eLA þ nLB þ 1  hð ÞvT  g þ d þ mið ÞI
dIm
dt
¼ eLAm þ nLBm þ hvT þ vTm  g þ dm þ mið ÞImdT
dt
¼ dI  ’ þ v þ mtð ÞT
dTm
dt
¼ dmIm  ’m þ v þ mt
 
Tm
Where:
N ¼ SA þ SB þ LA þ LB þ LAm þ LBm þ I þ Im þ T þ Tm
The parameter values used in the model and Figures 2–4 are
shown in Table A1 below.
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